Flow cytometric evaluation of measurable residual disease in chronic lymphocytic leukemia: Where do we stand?
chronic lymphocytic leukemia
flow cytometry
measurable residual disease
Journal
Hematological oncology
ISSN: 1099-1069
Titre abrégé: Hematol Oncol
Pays: England
ID NLM: 8307268
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
revised:
09
05
2022
received:
16
03
2022
accepted:
21
05
2022
pubmed:
7
6
2022
medline:
15
12
2022
entrez:
6
6
2022
Statut:
ppublish
Résumé
Measurable residual disease (MRD) has emerged as a relevant parameter of response to therapy in chronic lymphocytic leukemia (CLL). Although several methods have been developed, flow cytometry has emerged as the most useful and standardized approach to measure and quantify MRD. The improved sensitivity of MRD measurements has been paralleled by the development of more effective therapeutic strategies for CLL, increasing the applicability of MRD detection in this setting. Chemotherapy and chemoimmunotherapy have firstly demonstrated their ability to obtain a deep MRD. Combined targeted therapies are also demonstrating a high molecular response rate and prospective trials are exploring the role of MRD to guide the duration of treatment in this setting. In this review we briefly summarize what we have learned about MRD with emphasis on its flow cytometric detection.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
835-842Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745-2760. https://doi.org/10.1182/blood-2017-09-806398
Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(1):23-33. https://doi.org/10.1016/j.annonc.2020.09.019
Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol. 2005;23(13):2971-2979. https://doi.org/10.1200/JCO.2005.04.021
Bottcher S, Ritgen M, Fischer K, et al. Minimal residual disease quantification is an independent predictor of progression-free survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012;30(9):980-988. https://doi.org/10.1200/JCO.2011.36.9348
Kater AP, Seymour JF, Hillmen P, et al. Fixed duration of venetoclax rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study. J Clin Oncol. 2019;37(4):269-277. https://doi.org/10.1200/JCO.18.01580
Egle A, Steurer M, Melchardt T, et al. Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study. Anna Hematol. 2018;97(10):1825-1839. https://doi.org/10.1007/s00277-018-3380-z
Abrisqueta P, Villamor N, Terol MJ, et al. Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia. Blood. 2013;122(24):3951-3959. https://doi.org/10.1182/blood-2013-05-502773
Appleby N, O’Brien D, Quinn FM, et al. Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in no-del17(p) CLL. Leuk Lymphoma. 2018;59(6):1338-1347. https://doi.org/10.1080/10428194.2017.1376746
Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012;30(26):3209-3216. https://doi.org/10.1200/JCO.2011.39.2688
Frankfurt O, Ma S, Gordon L, et al. Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomes. Leuk Lymphoma. 2015;56(2):315-323. https://doi.org/10.3109/10428194.2014.910654
Short NJ, Keating MJ, Wierda WG, et al. Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia. Cancer. 2015;121(21):3869-3876. https://doi.org/10.1002/cncr.29605
Strati P, Keating MJ, O’Brien SM, et al. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood. 2014;123(24):3727-3732. https://doi.org/10.1182/blood-2013-11-538116
Thompson PA, Tam CS, O’Brien S, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016;127(3):303-309. https://doi.org/10.1182/blood-2015-09-667675
Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101-1110. https://doi.org/10.1056/NEJMoa1313984
Greil R, Obrtlikova P, Smolej L, et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8° Mabtenance randomised trial. Lancet Haematol. 2016;3(7):e317-329. https://doi.org/10.1016/S2352-3026(16)30045-X
Kovacs G, Robrecht S, Fink AM, et al. Minimal residual disease assessment improve prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of two phase III studies of the German CLL study group. J Clin Oncol. 2016;34(31):3758-3765. https://doi.org/10.1200/JCO.2016.67.1305
Santacruz R, Villamor N, Aymerich M, et al. The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy. Haematologica. 2014;99(5):873-880. https://doi.org/10.3324/haematol.2013.099796
Jones JA, Mato AR, Wierda WG, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet. 2018;19(1):65-75. https://doi.org/10.1016/S1470-2045(17)30909-9
Fraser G, Cramer P, Demirkan F, et al. Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia. 2019;33(4):969-980. https://doi.org/10.1038/s41375-018-0276-9
Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial. J Clin Oncol. 2018;36(19):1973-2198. https://doi.org/10.1200/JCO.2017.76.6840
Kwok M, Rawstron AC, Varghese A, et al. Minimal residual disease is an independent predictor for 10-year survival in CLL. Blood. 2016;128(24):2770-2773. https://doi.org/10.1182/blood-2016-05-714162
Wierda WG, Allan JN, Siddiqi T, et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study. J Clin Oncol. 2021;39(34):3853-3865. https://doi.org/10.1200/JCO.21.00807
Huber H, Edenhofer S, vonTresckow J, et al. Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline therapy for high-risk chronic lymphocytic leukemia. Blood. 2022;13(9):1318-1329. https://doi.org/10.1182/blood.2021013208
Burger JA, O’Brien S. Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy. Nat Rev Clin Oncol. 2018;15(8):510-527. https://doi.org/10.1038/s41571-018-0037-8
Cramer P, von Tresckow J, Bahlo J, et al. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19(9):1215-1228. https://doi.org/10.1016/S1470-2045(18)30414-5
Eichhorst B, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006;107(3):885-891. https://doi.org/10.1182/blood-2005-06-2395
Wang XV, Hanson CA, Tschumper RC, et al. Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. Blood. 2021;138(26):2810-2827. https://doi.org/10.1182/blood.2020010146
Dimier N, Delmar P, Ward C, et al. A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL. Blood. 2018;131(9):955-962. https://doi.org/10.1182/blood-2017-06-792333
European Medicines Agency. Appendix 4 to the guideline on the evaluation of anticancer medicinal products in man - condition specific guidance. Ref number EMA/CHMP/703715/2012 Rev. 2. Published Feb 15, 2016.
Wierda GW, Rawstron A, Cymbalista F, et al. Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. Leukemia. 2021;35(11):3059-3072. https://doi.org/10.1038/s41375-021-01241-1
D’Arena G, Volpe S, Amodeo R, et al. Italian Cytometry Society (GIC) endorsement of consensus recommendations for measurable residual disease in chronic lymphocytic leukemia. Int J Lab Hematol. 2021;18(3). https://doi.org/10.1111/ijlh.13766
Thompson PA, Srivastava J, Peterson C, et al. Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. Blood. 2019;134(22):1951-1959. https://doi.org/10.1182/blood.2019001077
Rawstron AC, Villamor N, Ritgen M, et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukemia. Leukemia. 2007;21(5):956-964. https://doi.org/10.1038/sj.leu.2404584
Rawstron AC, Bottcher S, Letestu R, et al. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the International harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia. 2013;27(1):142-149. https://doi.org/10.1038/leu.2012.216
Rawstron AC, Fazi C, Agathangelidis A, et al. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia. 2016;30(4):929-936. https://doi.org/10.1038/leu.2015.313
Farren TW, Giustiniani J, Fanous M, et al. Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia. Blood Cancer J. 2015;5(1):e273. https://doi.org/10.1038/bcj.2014.92
Farren TW, Sadanand KS, Agrawal SG. Highly sensitive and accurate assessment of minimal residual disease in chronic lymphocytic leukemia using the novel CD160-ROR1 assay. Front Oncol. 2020;10:597730. https://doi.org/10.3389/fonc.2020.597730
Stehlíková O, Chovancová J, Tichý B, et al. Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice. Int J Lab Hematol. 2014;36(2):165-171. https://doi.org/10.1111/ijlh.12149
Dowling AK, Liptrot SD, O’Brien D, Vandenberghe E. Optimization and validation of an 8-color single-tube Assay for the sensitive detection of minimal residual disease in B-cell chronic lymphocytic leukemia detected via flow cytometry. Lab Med. 2016;47(2):103-111. https://doi.org/10.1093/labmed/lmw006
Patz M, Pentok B, Cremer K, et al. ROR-1 is a highly discriminative marker in flow cytometric minimal residual disease (MRD) detection in chronic lymphocytic leukemia/CLL). Blood. 2016;128(22):3197. https://doi.org/10.1182/blood.V128.22.3197.3197
Sartor MM, Gottlieb DJ. A single tube 10-color flow cytometry assay optimizes detection of minimal residual disease in chronic lymphocytic leukemia. Cytometry B Clin Cytom. 2013;84(2):96-103. https://doi.org/10.1002/cyto.b.21067
Bento L, Correia R, deSousa F, et al. Performance of eight-color dry antibody reagent in the detection of minimal residual disease in chronic lymphocytic leukemia samples. Cytometry B Clin Cytom. 2020;98(6):529-535. https://doi.org/10.1002/cyto.b.21875